Here, we describe the most promising small synthetic organic compounds that act as potent Sortase A inhibitors and cater the potential to be developed as antivirulence drugs. Sortase A is a polypeptide of 206 amino acids, which catalyzes two sequential reactions: (i) thioesterification and (ii) transpeptidation. Sortase A is involved in the process of bacterial adhesion by anchoring LPXTG-containing proteins to lipid II. Sortase A inhibitors do not affect bacterial growth, but they restrain the virulence of pathogenic bacterial strains, thereby preventing infections caused by Staphylococcus aureus or other Gram-positive bacteria. The efficacy of the most promising inhibitors needs to be comprehensively evaluated in in vivo models of infection, in order to select compounds eligible for the treatment of bacterial infections in humans.
Cascioferro, S., Raffa, D., Maggio, B., Raimondi, M., Schillaci, D., Daidone, G. (2015). Sortase A Inhibitors: Recent Advances and Future Perspectives. JOURNAL OF MEDICINAL CHEMISTRY, 58(23), 9108-9123 [10.1021/acs.jmedchem.5b00779].
Sortase A Inhibitors: Recent Advances and Future Perspectives
CASCIOFERRO, Stella Maria
;RAFFA, Demetrio;MAGGIO, Benedetta
;RAIMONDI, Maria Valeria;SCHILLACI, Domenico;DAIDONE, Giuseppe
2015-12-10
Abstract
Here, we describe the most promising small synthetic organic compounds that act as potent Sortase A inhibitors and cater the potential to be developed as antivirulence drugs. Sortase A is a polypeptide of 206 amino acids, which catalyzes two sequential reactions: (i) thioesterification and (ii) transpeptidation. Sortase A is involved in the process of bacterial adhesion by anchoring LPXTG-containing proteins to lipid II. Sortase A inhibitors do not affect bacterial growth, but they restrain the virulence of pathogenic bacterial strains, thereby preventing infections caused by Staphylococcus aureus or other Gram-positive bacteria. The efficacy of the most promising inhibitors needs to be comprehensively evaluated in in vivo models of infection, in order to select compounds eligible for the treatment of bacterial infections in humans.File | Dimensione | Formato | |
---|---|---|---|
acs.jmedchem.5b00779.pdf
Solo gestori archvio
Descrizione: Articolo principale
Tipologia:
Versione Editoriale
Dimensione
5.46 MB
Formato
Adobe PDF
|
5.46 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.